This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ANA975

Roche Holding AG

Drug Names(s): ANA975

Description: ANA975 is an oral prodrug of Anadys' proprietary small molecule compound isatoribine, an agonist of Toll-Like Receptor 7 (TLR7). Activation of TLR7 can stimulate the immune system to combat viral infections.

Deal Structure: On June 2, 2005, Anadys Pharmaceuticals entered into an exclusive global license and co-development agreement with Novartis to develop, manufacture and commercialize ANA975 and additional Toll-Like Receptor 7 (TLR7) oral prodrugs. In addition to upfront and milestone payments, the agreement includes potential royalty payments and a U.S. co-promotion option for Anadys.

Under the terms of the agreement, Novartis will make an initial license payment of $20 million to Anadys. Anadys is also eligible to receive up to $550 million in regulatory and commercial milestone payments.

In addition, Anadys has a co-promotion option to retain 35 percent of profits in the U.S. by contributing 35 percent of the commercialization costs in the U.S.

In October 2011, Anadys announced that it has entered into a definitive merger agreement to be acquired by Roche. Under the terms of the merger agreement, Roche will commence an all cash tender offer for all outstanding shares of common stock of...See full deal structure in Biomedtracker

Partners: Novartis AG


ANA975 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug